Trial of Controversial Alzheimer’s Drug Halted After Disappointing ...
2 days ago · Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer’s drug, ending a long-contested bid for ...
Controversial Alzheimer’s drug from Cassava Sciences fails
2 days ago · It had claimed a phase 2 trial showed dramatic improvements in Alzheimer’s patients. Cassava’s original CEO, Remi Barbier, and one of the company’s chief scientists, Lindsay Burns, left the company, paid fines as part of their own SEC settlements, and were barred by SEC from serving as officers or directors of a public company for several ...
Cassava shares sink on plans to stop Alzheimer's drug studies
3 days ago · Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.
A Controversial Alzheimer's Drug Has Gone Down in Flames
1 day ago · Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent research.
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
3 days ago · In the meantime, Cassava is ending a second Phase III trial called ReFocus-ALZ, which evaluated a different dose of simufilam, as well as an expanded access program. Cassava’s shares plunged 85% to $3.91 as the markets opened Monday morning, compared to $26.48 at the previous close. The clinical failure caps a tumultuous few years for Cassava.
'Disappointing': Cassava Sciences Ends Study Of Alzheimer's …
2 days ago · The New York Times: Trial Of Controversial Alzheimer’s Drug Halted After Disappointing Results Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer’s drug, ending a long-contested bid for regulatory approval.
Cassava Sciences and its Alzheimer's drug are done. The damage …
3 days ago · The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
Jul 18, 2024 · Two top officials at Cassava Sciences — a small pharmaceutical company in Austin, Texas, embroiled in years of controversy over a proposed Alzheimer’s drug — have resigned.
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
Oct 2, 2024 · Cassava has promoted simufilam as a potential breakthrough drug for Alzheimer’s disease, which affects more than six million Americans and has virtually no effective treatments.
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
Sep 26, 2024 · Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of...
- Some results have been removed